Pharmacist-Led Patient Self-Testing Superior to Usual Care for Warfarin Management in Mechanical Heart Valve Patients: Evidence from a Multicentre RCT in China
Posted inCardiology Internal Medicine news

Pharmacist-Led Patient Self-Testing Superior to Usual Care for Warfarin Management in Mechanical Heart Valve Patients: Evidence from a Multicentre RCT in China

A multicentre RCT in China found that pharmacist-led patient self-testing (PST) significantly improves time in therapeutic range and reduces major bleeding and thromboembolism in patients with mechanical heart valves compared to traditional outpatient clinic care.
Delirium as a Sentinel Event: New UK Biobank Data Links Acute Brain Failure to Decades of Multisystem Vulnerability
Posted inInternal Medicine Neurology news

Delirium as a Sentinel Event: New UK Biobank Data Links Acute Brain Failure to Decades of Multisystem Vulnerability

A large-scale matched cohort study from the UK Biobank identifies in-hospital delirium as a sentinel marker for long-term multisystem vulnerability. Associated with increased risks of sepsis, AKI, and falls, delirium signals a profound physiological decline that persists independently of pre-existing frailty or dementia.
Beyond Pediatric Survival: The Disproportionate Impact of Childhood-Onset Complex Chronic Conditions on Adult Hospital Systems
Posted inInternal Medicine news Pediatrics

Beyond Pediatric Survival: The Disproportionate Impact of Childhood-Onset Complex Chronic Conditions on Adult Hospital Systems

This study reveals that young adults with childhood-onset complex chronic conditions (4Cs) account for over 10% of hospital bed-days despite being a small patient volume. They face longer stays, higher costs, and frequent readmissions, highlighting a critical gap in adult-oriented management for this vulnerable population.
Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control
Posted inDiabetes & Endocrinology Internal Medicine news

Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control

This Phase 1 study reveals that LY3537021, a long-acting GIPR agonist, independently drives significant weight loss and improves glucose regulation with a favorable safety profile and a 12-day half-life, clarifying the distinct therapeutic role of GIP in metabolic disease management.